/ /

  • linkedin
  • Increase Font
  • Sharebar

    Intranasal neurostimulator shows benefit for increasing tear production


    Favorable safety

    The majority of adverse events reported in the trials were mild or moderate in severity. The most common device-related adverse events reported in the second trial were nasal pain, discomfort or burning (10%) followed by nosebleed and transient electrical discomfort (5% each).

    “No serious device-related adverse events were reported in either study,” Dr. Holland said.

    Expert insights

    Dr. Holland said that in addition to stimulating aqueous tear production, there is evidence that the treatment stimulates mucin and meibomian gland secretions. He posited that the resulting improvement in tear film quality enables ocular surface healing over time, leading to symptom relief and resulting in decreased use of the device.

    “We were concerned that over time, the number of applications per day would increase,” he observed. “What we found in one trial was that usage actually decreased over time, and I think that is because the treatment is affecting the three major components of the tear film.”

    Dr. Holland also noted that the treatment was well-received by patients.

    “I did not think patients would want to use it, but we had no problems recruiting for the studies,” he said.

    He noted that patients need to be given good education so that they will use the device properly.
    “People tend to insert the tips barely into the nose and posteriorly. To be effective and hit the nerve target, the tips have to be positioned fairly superior and anterior,” Dr. Holland explained.

    Dr. Holland is a consultant for Allergan and to other companies marketing and developing treatments for DED.


    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results